Who are Ocaliva's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kybella, Cholbam, Chenix, Prelone, Kybella, Cholbam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/obeticholic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Ocaliva — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ocaliva (OBETICHOLIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Farnesoid X Receptor Agonist. Area: Metabolic.

marketed Farnesoid X Receptor Agonist Bile acid receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Ocaliva (OBETICHOLIC ACID) — Intercept Pharms Inc.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ocaliva TARGET	OBETICHOLIC ACID	Intercept Pharms Inc	marketed	Farnesoid X Receptor Agonist	Bile acid receptor	2016-01-01
Kybella	DEOXYCHOLIC ACID	AbbVie	marketed	Cytolytic Agent [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Cholbam	CHOLIC ACID	Mirum	marketed	Bile Acid [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Chenix	CHENODIOL		marketed	Bile Acid [EPC]	Bile acid receptor	1983-01-01
Prelone	prednisolone	Generic (originally Schering)	marketed	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Kybella	Kybella	Massachusetts General Hospital	marketed		G-protein coupled bile acid receptor 1, fMet-Leu-Phe receptor, Bile acid receptor
Cholbam	Cholbam	Mirum Pharmaceuticals, Inc.	marketed		G-protein coupled bile acid receptor 1, Bile acid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Farnesoid X Receptor Agonist class)

Intercept Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ocaliva — Competitive Intelligence Brief. https://druglandscape.com/ci/obeticholic-acid. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing